Riders · The University of Texas Rio Grande Valley School of Medicine · Article III: Agencies of Education

Cancer Center

Rider 7 in the 2026-27 Act, page III-236

Through the session

  1. 2024-25 Act Not in this version
  2. Introduced (Senate) Not in this version
  3. Introduced (House) Not in this version
  4. Senate substitute Not in this version
  5. House substitute New rider 7
  6. House passed Unchanged rider 7
  7. Conference Amended rider 7
  8. 2026-27 Act Unchanged rider 7

Pick any two steps to compare their wording.

What changed in the text

House passed → Conference: 5 passages changed.

Cancer Immunology Center. Out of funds appropriated above in Strategy D.1.2, Cancer Center/Cancer Research, $2,500,000 from the General Revenue Fund in fiscal year 2026 and $2,500,000 from the General Revenue Fund in fiscal year 2027 shall be used for to support clinical operations and research at the institution’s Cancer Immunology and Surgery Center. All Any unexpended balances as of August 31, 2026, are appropriated for the same purpose for the fiscal year beginning on September 1, 2026.

Removed words are struck through; added words are underlined. Sources: House passed · Conference.

Every version: numbers, statuses and source pages
VersionRider Against the version beforeAgainst the current budget Source
2024-25 ActGeneral Appropriations Act, 2024-25 Biennium Not in this version
Introduced (Senate)Senate Bill 1 as introduced (LBB recommended, Senate) Not in this version
Introduced (House)House Bill 1 as introduced (LBB recommended, House) Not in this version
Senate substituteCommittee Substitute for Senate Bill 1 Not in this version
House substituteHouse Committee Substitute for Senate Bill 1 7 New New Page III-199
House passedSenate Bill 1 as passed the second house 7 Unchanged New Page III-199
ConferenceConference Committee Report for Senate Bill 1 7 Amended New Page III-212
2026-27 ActGeneral Appropriations Act, 2026-27 Biennium 7 Unchanged New Page III-236
Full text of each wording

Conference, 2026-27 Act

Source, page III-236

Cancer Center. Out of funds appropriated above in Strategy D.1.2, Cancer Center/Cancer Research, $2,500,000 from the General Revenue Fund in fiscal year 2026 and $2,500,000 from the General Revenue Fund in fiscal year 2027 shall be used to support clinical operations and research at the institution’s Cancer and Surgery Center. Any unexpended balances as of August 31, 2026, are appropriated for the same purpose for the fiscal year beginning on September 1, 2026.

House substitute, House passed

Source, page III-199

Cancer Immunology Center. Out of funds appropriated above in Strategy D.1.2, Cancer Center/Cancer Research, $2,500,000 from the General Revenue Fund in fiscal year 2026 and $2,500,000 from the General Revenue Fund in fiscal year 2027 shall be used for the Cancer Immunology Center. All unexpended balances as of August 31, 2026, are appropriated for the same purpose for the fiscal year beginning on September 1, 2026.